Nektar Therapeutics (NKTR) Capital Leases (2010 - 2017)

Nektar Therapeutics' Capital Leases history runs 8 years deep, the most recent figure standing at $1.1 million for Q2 2017.

• On a quarterly basis, Capital Leases fell 61.68% year-over-year to $1.1 million in Q2 2017; TTM through Jun 2017 was $1.1 million, a 61.68% decrease from a year earlier, with the FY2016 full-year figure at $2.2 million, up 107.18% from the prior year.
• Capital Leases slipped to $1.1 million in Q2 2017 per NKTR's latest filing, from $1.6 million in the prior quarter.
• Across five years, Capital Leases topped out at $10.8 million in Q1 2013 and bottomed at $1.1 million in Q2 2017.
• The 5-year median for Capital Leases is $3.7 million (2014), against an average of $4.6 million.
• Across the five-year window, Capital Leases slumped 75.0% in 2015 and surged 107.18% in 2016, its largest moves.
• Year by year, Capital Leases stood at $8.0 million in 2013, then sank by 48.58% to $4.1 million in 2014, then plunged by 74.08% to $1.1 million in 2015, then jumped by 107.18% to $2.2 million in 2016, then plunged by 52.5% to $1.1 million in 2017.
• Per Business Quant, the three latest NKTR Capital Leases figures stand at $1.1 million (Q2 2017), $1.6 million (Q1 2017), and $2.2 million (Q4 2016).